基于外泌体 microRNA 的临床前阿尔茨海默病预测模型：一项多中心研究。

Exosomal MicroRNA-Based Predictive Model for Preclinical Alzheimer's Disease: A Multicenter Study.

机构信息

Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.

出版信息

Biol Psychiatry. 2022 Jul 1;92(1):44-53. doi: 10.1016/j.biopsych.2021.12.015. Epub 2022 Jan 3.

DOI:10.1016/j.biopsych.2021.12.015

PMID:35221095

Abstract

BACKGROUND

Exosomal microRNAs (miRNAs) have been demonstrated to be biomarkers of Alzheimer's disease (AD). However, whether exosomal miRNAs can predict AD at the asymptomatic stage remains unclear.

METHODS

This study is a multicenter study with four independent datasets to verify the capacity of exosomal miRNAs to identify preclinical AD. Subjects were recruited from a Beijing center in the pilot study (dataset 1: subjects with AD, n = 20; control subjects, n = 20), from other centers across China (dataset 2: subjects with AD, n = 95; control subjects, n = 93), a longitudinal cohort (dataset 3: subjects with preclinical AD, n = 101; control subjects, n = 102), and a confirmation study on familial AD (dataset 4: mutation carriers, n = 56; nonmutation carriers, n = 57).

RESULTS

A panel of miRNAs was changed in subjects with AD and can detect preclinical AD 5 to 7 years before the onset of cognitive impairment (areas under the curve = 0.85-0.88).

CONCLUSIONS

Exosomal miRNAs can be effective biomarkers for predicting AD 5 to 7 years prior to cognitive impairment onset.

摘要

背景

外泌体 microRNAs（miRNAs）已被证明是阿尔茨海默病（AD）的生物标志物。然而，外泌体 miRNAs 是否能够在无症状阶段预测 AD 尚不清楚。

方法

本研究是一项多中心研究，有四个独立数据集，旨在验证外泌体 miRNAs 识别临床前 AD 的能力。受试者来自北京中心的试点研究（数据集 1：AD 患者，n=20；对照组，n=20）、中国其他中心（数据集 2：AD 患者，n=95；对照组，n=93）、纵向队列（数据集 3：临床前 AD 患者，n=101；对照组，n=102）和家族性 AD 的确认研究（数据集 4：突变携带者，n=56；非突变携带者，n=57）。